Cargando…
The prognosis of elderly patients with hepatocellular carcinoma: A multi‐center 19‐year experience in Japan
AIMS: This retrospective study compared the survival between elderly and non‐elderly patients. METHODS: A total of 5545 treatment‐naive patients with hepatocellular carcinoma (HCC) who visited 7 different hospitals from January 2000 to December 2018 were included. Patients ≥80 years old were defined...
Autores principales: | Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Kariyama, Kazuya, Tsuji, Kunihiko, Ishikawa, Toru, Toyoda, Hidenori, Yasuda, Satoshi, Naganuma, Atsushi, Tada, Toshifumi, Takaguchi, Koichi, Tsutsui, Akemi, Itobayashi, Ei, Shimada, Noritomo, Shibata, Hiroshi, Tanaka, Takaaki, Nagano, Takuya, Imai, Michitaka, Nakamura, Shinichiro, Nouso, Kazuhiro, Kosaka, Hisashi, Kaibori, Masaki, Kumada, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844645/ https://www.ncbi.nlm.nih.gov/pubmed/35608226 http://dx.doi.org/10.1002/cam4.4850 |
Ejemplares similares
-
Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality
por: Hiraoka, Atsushi, et al.
Publicado: (2023) -
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2018) -
Role of hepatic resection in patients with intermediate‐stage hepatocellular carcinoma: A multicenter study from Japan
por: Tada, Toshifumi, et al.
Publicado: (2017) -
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
por: Hatanaka, Takeshi, et al.
Publicado: (2022) -
Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)